片仔癀(600436.SH)：PZH2107Ⅱ期临床试验完成首例受试者入组

智通财经02-10

智通财经APP讯，片仔癀(600436.SH)发布公告，近日，公司与上海璃道医药科技有限公司(简称“璃道医药”)合作研发项目—PZH2107(璃道医药内部研发项目代号：LDS片)，已完成“LDS片治疗纤维肌痛的随机、双盲、安慰剂平行对照、多中心、Ⅱ期临床试验”的首例受试者入组，正式进入Ⅱ期临床试验。PZH2107Ⅱ期临床试验采用随机、双盲、安慰剂平行对照、多中心、临床试验设计，其主要目的为：1.以...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2610610047?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-10 17:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610610047","market":"sh","top_or_hot":-1,"title":"片仔癀(600436.SH)：PZH2107Ⅱ期临床试验完成首例受试者入组","media":"智通财经","content":"<div>\n<p>智通财经APP讯，片仔癀(600436.SH)发布公告，近日，公司与上海璃道医药科技有限公司(简称“璃道医药”)合作研发项目—PZH2107(璃道医药内部研发项目代号：LDS片)，已完成“LDS片治疗纤维肌痛的随机、双盲、安慰剂平行对照、多中心、Ⅱ期临床试验”的首例受试者入组，正式进入Ⅱ期临床试验。PZH2107Ⅱ期临床试验采用随机、双盲、安慰剂平行对照、多中心、临床试验设计，其主要目的为：1.以...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1403699.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>片仔癀(600436.SH)：PZH2107Ⅱ期临床试验完成首例受试者入组</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n片仔癀(600436.SH)：PZH2107Ⅱ期临床试验完成首例受试者入组\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-10 17:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1403699.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，片仔癀(600436.SH)发布公告，近日，公司与上海璃道医药科技有限公司(简称“璃道医药”)合作研发项目—PZH2107(璃道医药内部研发项目代号：LDS片)，已完成“LDS片治疗纤维肌痛的随机、双盲、安慰剂平行对照、多中心、Ⅱ期临床试验”的首例受试者入组，正式进入Ⅱ期临床试验。PZH2107Ⅱ期临床试验采用随机、双盲、安慰剂平行对照、多中心、临床试验设计，其主要目的为：1.以...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1403699.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1403699.html","article_id":"2610610047","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610610047","pubTimestamp":1770714453,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，片仔癀 发布公告，近日，公司与上海璃道医药科技有限公司合作研发项目—PZH2107，已完成“LDS片治疗纤维肌痛的随机、双盲、安慰剂平行对照、多中心、Ⅱ期临床试验”的首例受试者入组，正式进入Ⅱ期临床试验。该临床试验方案已获得牵头单位中国医学科学院北京协和医院药物临床试验伦理委员会审查批准，并于2026年2月8日完成首例受试者入组。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600436":"片仔癀","BK0196":"行业龙头","BK0239":"医药制造","BK0028":"国家队","BK0188":"融资融券"},"translate_title":"Pien Tze Huang (600436. SH): PZH2107 phase II clinical trial completed the first subject enrollment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600436":1.5},"content_text":"智通财经APP讯，片仔癀(600436.SH)发布公告，近日，公司与上海璃道医药科技有限公司(简称“璃道医药”)合作研发项目—PZH2107(璃道医药内部研发项目代号：LDS片)，已完成“LDS片治疗纤维肌痛的随机、双盲、安慰剂平行对照、多中心、Ⅱ期临床试验”的首例受试者入组，正式进入Ⅱ期临床试验。PZH2107Ⅱ期临床试验采用随机、双盲、安慰剂平行对照、多中心、临床试验设计，其主要目的为：1.以安慰剂为对照，初步评价LDS片治疗纤维肌痛的有效性和安全性;2.探索LDS片治疗纤维肌痛的最佳有效剂量，为Ⅲ期临床试验提供依据。该临床试验的主要终点为“治疗后第12周疼痛NRS周平均评分(1周内每日疼痛评分后计算的平均值)较基线的变化”。该临床试验方案已获得牵头单位中国医学科学院北京协和医院药物临床试验伦理委员会审查批准，并于2026年2月8日完成首例受试者入组。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610610047","isCrawlerRequest":true}